How I treat older patients with AML

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

1997 • 1,200 citations

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

1997 • 897 citations

A randomized placebo-controlled phase III study of granulocyte- macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490)

1995 • 462 citations

Granulocyte–Macrophage Colony-Stimulating Factor after Initial Chemotherapy for Elderly Patients with Primary Acute Myelogenous Leukemia

1995 • 458 citations

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study

1996 • 423 citations

On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group.

1989 • 395 citations

DNA Methylation

1999 • 341 citations

Management of Acute Myeloid Leukemia in Elderly Patients

1999 • 247 citations

Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy

1997 • 238 citations

Varying intensity of postremission therapy in acute myeloid leukemia

1992 • 228 citations

Basic principles and practice

1994 • 189 citations

Randomized Phase II Study of Fludarabine + Cytosine Arabinoside + Idarubicin ± All-Trans Retinoic Acid ± Granulocyte Colony-Stimulating Factor in Poor Prognosis Newly Diagnosed Acute Myeloid Leukemia and Myelodysplastic Syndrome

1999 • 180 citations

Full dose versus attenuated dose daunorubicin, cytosine arabinoside, and 6-thioguanine in the treatment of acute nonlymphocytic leukemia in the elderly.

1984 • 149 citations

Acute myelogenous leukaemia in the elderly: retrospective study of 235 consecutive patients

1994 • 123 citations

Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia

1996 • 103 citations

Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission.

1985 • 100 citations

Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia.

1989 • 97 citations

Implications of Potential Cure in Acute Myelogenous Leukemia: Development of Subsequent Cancer and Return to Work

1997 • 88 citations

Treatment of newly‐diagnosed acute myelogenous leukaemia in patients aged 80 years and above

1996 • 63 citations

Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.

1996 • 52 citations

A bayesian strategy for screening cancer treatments prior to phase ii clinical evaluation

1993 • 43 citations

Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

1999 • 34 citations

Prognostic Factors in Elderly Patients with Acute Myeloid Leukaemia

1994 • 19 citations

Smoldering Acute Granulocytic Leukemia

1983 • 16 citations

Validation of a model to predict survival in elderly patients with acute myeloid leukaemia

1995 • 16 citations

Attenuated High-Dose Cytosine Arabinoside in the Treatment of the Elderly Patient with Acute Nonlymphocytic Leukemia

1989 • 9 citations

NCCN Acute Leukemia Practice Guidelines. The National Comprehensive Cancer Network.

1996 • 6 citations

Cited By (0)

Loading...